Business
Catheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook
FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital work
About this update from Catheter Precision, Inc.
[{"type":"image","alt":"Catheter Precision, Inc.","displaySize":"","headline":null,"caption":"Catheter Precision, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":274,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YQBzazT126278wVP0b5CKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5","width":274,"height":58}},"lazy":false},{"type":"text","content":"FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital workflows.","length":510,"tagName":"p"},{"type":"text","content":"Following its highest recorded revenue for the month of January, and following its recent entry into several international markets, Catheter Precision has secured approval for evaluations at several additional influential high-volume centers throughout the Unites States. These evaluations are a critical precursor to long-term purchasing agreements, allowing clinical teams to validate LockeT’s efficacy and additional adoption at affiliated hospitals within a network.","length":470,"tagName":"p"},{"type":"text","content":""The initial feedback from our newest hospital partners confirms that LockeT addresses a critical need for efficient, cost-effective wound closure," said David Jenkins, CEO of Catheter Precision. "We are entering 2026 with a strong pipeline of evaluations that we expect will transition into permanent adoption, further solidifying our position in the global electrophysiology market. Those hospitals where we have completed evaluations, or shortly expect to complete evaluations, are among hospitals of the highest repute, including John’s Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California."","length":695,"tagName":"p"},{"type":"text",...